Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198771 | 0.85 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL1198000 | 0.81 | SMN1; SMN2 (0.36) | SMN1; SMN2KMT2ACYP2C19CYP3A4LMNA | |
| SCHEMBL19208815 | 0.76 | NPC1 (0.57) | SMN1; SMN2KMT2ACYP2C19MEN1CYP3A4 | |
| SCHEMBL31518503 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2KMT2AMAPK1CYP2C19CYP2C9 | |
| SCHEMBL13024307 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL20553301 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2AMAPK1CYP2C19MEN1 | |
| SCHEMBL12875698 | 0.73 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2ALMNANPC1GPR119 | |
| SCHEMBL13462878 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2KMT2ACYP2C19LMNANPC1 | |
| SCHEMBL29821194 | 0.73 | KDM4E (0.47) | SMN1; SMN2KMT2ACYP2C19CYP2C9MEN1 | |
| SCHEMBL12875695 | 0.72 | KMT2A (0.51) | SMN1; SMN2KMT2ACYP2C19MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461348-B2 | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | SMN1; SMN2 2057/4885KMT2A 3197/4885MAPK1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.